Lymphocytes in atherosclerosis

Clinica Chimica Acta

Volumn 413, Issue 19-20, 2012, Pages 1562-1568

  Wigren, Maria ^a   Nilsson, Jan ^a   Kolbus, Daniel ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Adaptive immunity; Atherosclerosis; Immune therapy; Regulatory T cells; Th1 cells

Indexed keywords

APOLIPOPROTEIN B; AUTOANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE; HEAT SHOCK PROTEIN 60;

ANTIGEN PRESENTING CELL; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE COURSE; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; HYPERCHOLESTEROLEMIA; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; VACCINATION;

ANIMALS; ANTIGEN-PRESENTING CELLS; ATHEROSCLEROSIS; AUTOANTIBODIES; AUTOANTIGENS; B-LYMPHOCYTES; DISEASE PROGRESSION; HUMANS; IMMUNE SYSTEM; INFLAMMATION; LIPOPROTEINS, LDL; MICE; PLAQUE, ATHEROSCLEROTIC; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

EID: 84864391537     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.04.031     Document Type: Review

References (105)

1. Dworacka M., Winiarska H., Borowska M., Abramczyk M., Bobkiewicz-Kozlowska T., Dworacki G. Pro-atherogenic alterations in T-lymphocyte subpopulations related to acute hyperglycaemia in type 2 diabetic patients. Circ J 2007, 71(6):962-967. [Epub 2007/05/29].
2. Szodoray P., Timar O., Veres K., et al. TH1/TH2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines-immunological alterations in acute coronary syndrome and stable coronary artery disease. Scand J Immunol 2006, 64(3):336-344. [Epub 2006/08/22].
3. Nunez J., Minana G., Bodi V., et al. Low lymphocyte count and cardiovascular diseases. Curr Med Chem 2011, 18(21):3226-3233. [Epub 2011/06/16].
4. Zhou X., Nicoletti A., Elhage R., Hansson G.K. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 2000, 102(24):2919-2922. [Epub 2000/01/11].
5. Zhou X., Robertson A.K., Rudling M., Parini P., Hansson G.K. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. Circ Res 2005, 96(4):427-434. [Epub 2005/01/22].
6. + T lymphocytes leads to opposite effects on site-specific atherosclerosis in female apolipoprotein E-deficient mice. Am J Pathol 2004, 165(6):2013-2018. [Epub 2004/12/08].
7. Buono C., Binder C.J., Stavrakis G., Witztum J.L., Glimcher L.H., Lichtman A.H. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A 2005, 102(5):1596-1601. [Epub 2005/01/25].
8. Buono C., Come C.E., Stavrakis G., Maguire G.F., Connelly P.W., Lichtman A.H. Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol 2003, 23(3):454-460. [Epub 2003/03/05].
9. Branen L., Hovgaard L., Nitulescu M., Bengtsson E., Nilsson J., Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2004, 24(11):2137-2142. [Epub 2004/09/04].
10. Davenport P., Tipping P.G. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003, 163(3):1117-1125. [Epub 2003/08/26].
11. King V.L., Cassis L.A., Daugherty A. Interleukin-4 does not influence development of hypercholesterolemia or angiotensin II-induced atherosclerotic lesions in mice. Am J Pathol 2007, 171(6):2040-2047. [Epub 2007/12/07].
12. Kleemann R., Zadelaar S., Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008, 79(3):360-376. [Epub 2008/05/20].
13. Noelle R.J., Nowak E.C. Cellular sources and immune functions of interleukin-9. Nat Rev Immunol 2010, 10(10):683-687. [Epub 2010/09/18].
14. Caruso R., Stolfi C., De Nitto D., Pallone F., Monteleone G. The dual role of interleukin-25 in the control of immune-mediated pathologies. Curr Mol Med 2011, 11(1):26-30. [Epub 2010/12/30].
15. Binder C.J., Hartvigsen K., Chang M.K., et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 2004, 114(3):427-437. [Epub 2004/08/03].
16. Sampi M., Ukkola O., Paivansalo M., Kesaniemi Y.A., Binder C.J., Horkko S. Plasma interleukin-5 levels are related to antibodies binding to oxidized low-density lipoprotein and to decreased subclinical atherosclerosis. J Am Coll Cardiol 2008, 52(17):1370-1378. [Epub 2008/10/23].
17. Miller A.M., Xu D., Asquith D.L., et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008, 205(2):339-346. [Epub 2008/02/13].
18. Corthay A. How do regulatory T cells work?. Scand J Immunol 2009, 70(4):326-336. [Epub 2009/09/16].
19. de Boer O.J., van der Meer J.J., Teeling P., van der Loos C.M., van der Wal A.C. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS One 2007, 2(1):e779. [Epub 2007/08/23].
20. Veillard N.R., Steffens S., Burger F., Pelli G., Mach F. Differential expression patterns of proinflammatory and antiinflammatory mediators during atherogenesis in mice. Arterioscler Thromb Vasc Biol 2004, 24(12):2339-2344. [Epub 2004/10/02].
21. Wigren M., Bengtsson D., Duner P., et al. Atheroprotective effects of Alum are associated with capture of oxidized LDL antigens and activation of regulatory T cells. Circ Res 2009, 104(12):e62-e70. [Epub 2009/05/30].
22. Gotsman I., Grabie N., Gupta R., et al. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 2006, 114(19):2047-2055. [Epub 2006/10/25].
23. Ait-Oufella H., Salomon B.L., Potteaux S., et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006, 12(2):178-180. [Epub 2006/02/08].
24. van Es T., van Puijvelde G.H., Foks A.C., et al. Vaccination against Foxp3(+) regulatory T cells aggravates atherosclerosis. Atherosclerosis 2010, 209(1):74-80. [Epub 2009/09/22].
25. Mallat Z., Besnard S., Duriez M., et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999, 85(8):e17-e24. [Epub 1999/10/16].
26. Mallat Z., Gojova A., Marchiol-Fournigault C., et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 2001, 89(10):930-934. [Epub 2001/11/10].
27. Pinderski Oslund L.J., Hedrick C.C., Olvera T., et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999, 19(12):2847-2853. [Epub 1999/12/11].
28. Robertson A.K., Rudling M., Zhou X., Gorelik L., Flavell R.A., Hansson G.K. Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest 2003, 112(9):1342-1350. [Epub 2003/10/22].
29. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133(5):775-787. [Epub 2008/05/31].
30. Cvetanovich G.L., Hafler D.A. Human regulatory T cells in autoimmune diseases. Curr Opin Immunol 2010, 22(6):753-760. [Epub 2010/09/28].
31. + T cells by magnetic beads reveals two phenotypically and functionally different subsets. J Immunol Methods 2011, 369(1-2):59-68. [Epub 2011/04/26].
32. Mor A., Luboshits G., Planer D., Keren G., George J. Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J 2006, 27(21):2530-2537. [Epub 2006/09/07].
33. +CD25hiCD127lo regulatory T-Cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2010, 30(9):1832-1841. [Epub 2010/06/12].
34. Fyfe A.I., Qiao J.H., Lusis A.J. Immune-deficient mice develop typical atherosclerotic fatty streaks when fed an atherogenic diet. J Clin Invest 1994, 94(6):2516-2520. [Epub 1994/12/01].
35. -/- mice. Decreasing density with disease progression. Arterioscler Thromb Vasc Biol 1996, 16(8):1013-1018. [Epub 1996/08/01].
36. Gewaltig J., Kummer M., Koella C., Cathomas G., Biedermann B.C. Requirements for CD8 T-cell migration into the human arterial wall. Hum Pathol 2008, 39(12):1756-1762. [Epub 2008/08/19].
37. Ludewig B., Freigang S., Jaggi M., et al. Linking immune-mediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model. Proc Natl Acad Sci U S A 2000, 97(23):12752-12757. [Epub 2000/10/26].
38. Escalante N.K., von Rossum A., Lee M., Choy J.C. CD155 on human vascular endothelial cells attenuates the acquisition of effector functions in CD8 T cells. Arterioscler Thromb Vasc Biol 2011, 31(5):1177-1184. [Epub 2011/02/19].
39. -/- mice. BMC Immunol 2010, 11(1):58. [Epub 2010/12/04].
40. + T cells in patients with coronary artery disease: relation to cytomegalovirus infection. J Intern Med 2003, 254(5):472-478. [Epub 2003/10/11].
41. Bason C., Corrocher R., Lunardi C., et al. Interaction of antibodies against cytomegalovirus with heat-shock protein 60 in pathogenesis of atherosclerosis. Lancet 2003, 362(9400):1971-1977. [Epub 2003/12/20].
42. Rossmann A., Henderson B., Heidecker B., et al. T-cells from advanced atherosclerotic lesions recognize hHSP60 and have a restricted T-cell receptor repertoire. Exp Gerontol 2008, 43(3):229-237. [Epub 2008/01/30].
43. Benagiano M., D'Elios M.M., Amedei A., et al. Human 60-kDa heat shock protein is a target autoantigen of T cells derived from atherosclerotic plaques. J Immunol 2005, 174(10):6509-6517. [Epub 2005/05/10].
44. Nadareishvili Z.G., Koziol D.E., Szekely B., et al. Increased CD8(+) T cells associated with Chlamydia pneumoniae in symptomatic carotid plaque. Stroke 2001, 32(9):1966-1972. [Epub 2001/09/08].
45. + T cells in autoimmune disease. Hum Immunol 2008, 69(11):781-789. [Epub 2008/09/25].
46. + T lymphocytes from MHC class II-deficient mice exhibit regulatory activity. J Immunol 2005, 175(1):246-253. [Epub 2005/06/24].
47. + regulatory thymocytes. Blood 2003, 102(12):4107-4114. [Epub 2003/08/02].
48. + cell-induced colitis. J Immunol 2011, 186(1):41-52. [Epub 2010/11/26].
49. + T cells have the same function as murine CD8+CD122+ Treg. Eur J Immunol 2009, 39(8):2106-2119. [Epub 2009/07/18].
50. + T cells as regulatory versus memory T cells. J Immunol 2010, 185(2):803-807. [Epub 2010/06/16].
51. Gotsman I., Grabie N., Dacosta R., Sukhova G., Sharpe A., Lichtman A.H. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J Clin Invest 2007, 117(10):2974-2982. [Epub 2007/09/15].
52. -/- mice. Circulation 2010, 122:A18244.
53. Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect 2009, 11(5):625-630. [Epub 2009/04/18].
54. Milner J.D., Sandler N.G., Douek D.C. Th17 cells, Job's syndrome and HIV: opportunities for bacterial and fungal infections. Curr Opin HIV AIDS 2010, 5(2):179-183. [Epub 2010/06/15].
55. van Es T., van Puijvelde G.H., Ramos O.H., et al. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun 2009, 388(2):261-265. [Epub 2009/08/08].
56. Smith E., Prasad K.M., Butcher M., et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 2010, 121(15):1746-1755. [Epub 2010/04/07].
57. Gao Q., Jiang Y., Ma T., et al. A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J Immunol 2010, 185(10):5820-5827. [Epub 2010/10/19].
58. Madhur M.S., Funt S.A., Li L., et al. Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol 2011, 31(7):1565-1572. [Epub 2011/04/09].
59. Taleb S., Romain M., Ramkhelawon B., et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 2009, 206(10):2067-2077. [Epub 2009/09/10].
60. Dart M.L., Jankowska-Gan E., Huang G., et al. Interleukin-17-dependent autoimmunity to collagen type V in atherosclerosis. Circ Res 2010, 107(9):1106-1116. [Epub 2010/09/04].
61. Xie J.J., Wang J., Tang T.T., et al. The Th17/Treg functional imbalance during atherogenesis in ApoE(-/-) mice. Cytokine 2010, 49(2):185-193. [Epub 2009/10/20].
62. de Boer O.J., van der Meer J.J., Teeling P., et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol 2010, 220(4):499-508. [Epub 2009/12/19].
63. Wang Z., Lee J., Zhang Y., et al. Increased Th17 cells in coronary artery disease are associated with neutrophilic inflammation. Scand Cardiovasc J 2011, 45(1):54-61. [Epub 2011/01/14].
64. Eid R.E., Rao D.A., Zhou J., et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009, 119(10):1424-1432. [Epub 2009/03/04].
65. Zhao Z., Wu Y., Cheng M., et al. Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome. Atherosclerosis 2011, 217(2):518-524. [Epub 2011/04/29].
66. von Vietinghoff S., Koltsova E.K., Mestas J., Diehl C.J., Witztum J.L., Ley K. Mycophenolate mofetil decreases atherosclerotic lesion size by depression of aortic T-lymphocyte and interleukin-17-mediated macrophage accumulation. J Am Coll Cardiol 2011, 57(21):2194-2204. [Epub 2011/05/21].
67. Zhou X., Hansson G.K. Detection of B cells and proinflammatory cytokines in atherosclerotic plaques of hypercholesterolaemic apolipoprotein E knockout mice. Scand J Immunol 1999, 50(1):25-30. [Epub 1999/07/15].
68. Caligiuri G., Nicoletti A., Poirier B., Hansson G.K. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002, 109(6):745-753. [Epub 2002/03/20].
69. Major A.S., Fazio S., Linton M.F. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 2002, 22(11):1892-1898. [Epub 2002/11/12].
70. Ait-Oufella H., Herbin O., Bouaziz J.D., et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med 2010, 207(8):1579-1587. [Epub 2010/07/07].
71. Kyaw T., Tay C., Khan A., et al. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J Immunol 2010, 185(7):4410-4419. [Epub 2010/09/08].
72. Tsimikas S., Brilakis E.S., Lennon R.J., et al. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res 2007, 48(2):425-433. [Epub 2006/11/10].
73. Nilsson J., Nordin Fredrikson G., Schiopu A., Shah P.K., Jansson B., Carlsson R. Oxidized LDL antibodies in treatment and risk assessment of atherosclerosis and associated cardiovascular disease. Curr Pharm Des 2007, 13(10):1021-1030. [Epub 2007/04/14].
74. Nilsson J., Kovanen P.T. Will autoantibodies help to determine severity and progression of atherosclerosis?. Curr Opin Lipidol 2004, 15(5):499-503. [Epub 2004/09/14].
75. -/- mice via the complement system. Clin Exp Immunol 2005, 142(3):441-445. [Epub 2005/11/22].
76. Nicoletti A., Kaveri S., Caligiuri G., Bariety J., Hansson G.K. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 1998, 102(5):910-918. [Epub 1998/09/03].
77. Zhao M., Wigren M., Duner P., et al. FcgammaRIIB inhibits the development of atherosclerosis in low-density lipoprotein receptor-deficient mice. J Immunol 2010, 184(5):2253-2260. [Epub 2010/01/26].
78. Schiopu A., Bengtsson J., Soderberg I., et al. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 2004, 110(14):2047-2052. [Epub 2004/09/29].
79. Schiopu A., Frendeus B., Jansson B., et al. Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice. J Am Coll Cardiol 2007, 50(24):2313-2318. [Epub 2007/12/11].
80. Fredrikson G.N., Schiopu A., Berglund G., Alm R., Shah P.K., Nilsson J. Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis 2007, 194(2):e188-e192. [Epub 2007/01/12].
81. Sjogren P., Fredrikson G.N., Samnegard A., et al. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur Heart J 2008, 29(18):2218-2226. [Epub 2008/07/31].
82. Moos M.P., John N., Grabner R., et al. The lamina adventitia is the major site of immune cell accumulation in standard chow-fed apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005, 25(11):2386-2391. [Epub 2005/09/24].
83. Jongstra-Bilen J., Haidari M., Zhu S.N., Chen M., Guha D., Cybulsky M.I. Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis. J Exp Med 2006, 203(9):2073-2083. [Epub 2006/08/09].
84. Llodra J., Angeli V., Liu J., Trogan E., Fisher E.A., Randolph G.J. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci U S A 2004, 101(32):11779-11784. [Epub 2004/07/29].
85. Angeli V., Llodra J., Rong J.X., et al. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 2004, 21(4):561-574. [Epub 2004/10/16].
86. Koltsova E.K., Ley K. How dendritic cells shape atherosclerosis. Trends Immunol 2011, 32(11):540-547.
87. Weber C., Meiler S., Doring Y., et al. CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. J Clin Invest 2011, 121(7). [Epub 2011/06/03].
88. Stemme S., Faber B., Holm J., Wiklund O., Witztum J.L., Hansson G.K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1995, 92(9):3893-3897. [Epub 1995/04/25].
89. Ameli S., Hultgardh-Nilsson A., Regnstrom J., et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996, 16(8):1074-1079. [Epub 1996/08/01].
90. Yuan Z., Kishimoto C., Sano H., Shioji K., Xu Y., Yokode M. Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion. Am J Physiol Heart Circ Physiol 2003, 285(2):H899-H906. [Epub 2003/07/16].
91. Fredrikson G.N., Soderberg I., Lindholm M., et al. Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 2003, 23(5):879-884. [Epub 2003/03/22].
92. Nilsson J., Hansson G.K. Autoimmunity in atherosclerosis: a protective response losing control?. J Intern Med 2008, 263(5):464-478. [Epub 2008/04/16].
93. Nilsson J., Wigren M., Shah P.K. Regulatory T cells and the control of modified lipoprotein autoimmunity-driven atherosclerosis. Trends Cardiovasc Med 2009, 19(8):272-276. [Epub 2010/05/08].
94. Hermansson A., Johansson D.K., Ketelhuth D.F., Andersson J., Zhou X., Hansson G.K. Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice. Circulation 2011, 123(10):1083-1091. [Epub 2011/03/02].
95. Hjerpe C., Johansson D., Hermansson A., Hansson G.K., Zhou X. Dendritic cells pulsed with malondialdehyde modified low density lipoprotein aggravate atherosclerosis in Apoe(-/-) mice. Atherosclerosis 2010, 209(2):436-441. [Epub 2009/11/10].
96. Xu Q., Schett G., Perschinka H., et al. Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. Circulation 2000, 102(1):14-20. [Epub 2000/07/06].
97. Afek A., George J., Gilburd B., et al. Immunization of low-density lipoprotein receptor deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis. J Autoimmun 2000, 14(2):115-121. [Epub 2000/03/24].
98. Klingenberg R., Ketelhuth D.F., Strodthoff D., Gregori S., Hansson G.K. Subcutaneous immunization with heat shock protein-65 reduces atherosclerosis in Apoe(-/-) mice. Immunobiology 2012, 217(5):540-547.
99. Nystrom-Rosander C., Edvinsson M., Thelin S., Hjelm E., Friman G. Chlamydophila pneumonia: specific mRNA in aorta ascendens in patients undergoing coronary artery by-pass grafting. Scand J Infect Dis 2006, 38(9):758-763. [Epub 2006/08/30].
100. Borel N., Summersgill J.T., Mukhopadhyay S., Miller R.D., Ramirez J.A., Pospischil A. Evidence for persistent Chlamydia pneumoniae infection of human coronary atheromas. Atherosclerosis 2008, 199(1):154-161. [Epub 2007/11/22].
101. Curry A.J., Portig I., Goodall J.C., Kirkpatrick P.J., Gaston J.S. T lymphocyte lines isolated from atheromatous plaque contain cells capable of responding to Chlamydia antigens. Clin Exp Immunol 2000, 121(2):261-269. [Epub 2000/08/10].
102. Binder C.J., Horkko S., Dewan A., et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003, 9(6):736-743. [Epub 2003/05/13].
103. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. J Immunol 2004, 172(5):2731-2738. [Epub 2004/02/24].
104. Doeing D.C., Borowicz J.L., Crockett E.T. Gender dimorphism in differential peripheral blood leukocyte counts in mice using cardiac, tail, foot, and saphenous vein puncture methods. BMC Clin Pathol 2003, 3(1):3. [Epub 2003/09/16].
105. Goncalves I., Stenstrom K., Skog G., Mattsson S., Nitulescu M., Nilsson J. Short communication: dating components of human atherosclerotic plaques. Circ Res 2010, 106(6):1174-1177. [Epub 2010/02/20].